Parabilis Medicines (NASDAQ:PBLS) Upgraded at Zacks Research

Parabilis Medicines (NASDAQ:PBLS) was upgraded by analysts at Zacks Research to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

A number of other equities research analysts also recently commented on PBLS. Wall Street Zen upgraded Parabilis Medicines to a “hold” rating in a research report on Saturday, June 20th. Bank of America began coverage on Parabilis Medicines in a report on Monday. They set a “buy” rating and a $45.00 price target for the company. Leerink Partners started coverage on Parabilis Medicines in a research report on Monday. They set an “outperform” rating and a $40.00 price objective for the company. Guggenheim started coverage on shares of Parabilis Medicines in a report on Monday. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Lifesci Capital raised shares of Parabilis Medicines to a “strong-buy” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Parabilis Medicines presently has an average rating of “Buy” and an average price target of $41.67.

Parabilis Medicines Trading Up 1.6%

PBLS stock opened at $30.83 on Tuesday. Parabilis Medicines has a one year low of $24.51 and a one year high of $34.47.

Insiders Place Their Bets

In other news, Director Alan Sebulsky purchased 12,500 shares of the stock in a transaction dated Thursday, June 11th. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the transaction, the director directly owned 12,500 shares in the company, valued at approximately $250,000. This represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Guy Levy acquired 500,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was purchased at an average cost of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the purchase, the insider directly owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. This represents a 94.88% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 530,000 shares of company stock worth $10,723,528 over the last 90 days.

More Parabilis Medicines News

Here are the key news stories impacting Parabilis Medicines this week:

• Positive Sentiment: Lifesci Capital upgraded Parabilis Medicines to Strong-Buy, signaling increased confidence in the company’s outlook and supporting the stock’s recent strength. Lifesci Capital upgrade report
• Positive Sentiment: Guggenheim initiated coverage with a Buy rating and a $40.00 price target, suggesting upside potential and helping boost investor sentiment. Guggenheim coverage report
• Positive Sentiment: Bank of America and Leerink Partners also began analyst coverage, adding to the positive Wall Street attention around PBLS. Bank of America coverage Leerink Partners coverage
• Neutral Sentiment: Lifesci Capital also published a full set of earnings estimates for 2026 and 2027, including expected losses for most quarters and fiscal years. While these forecasts provide more visibility, they do not appear to be a fresh catalyst by themselves. PBLS analyst estimates